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ABSTRACT
Objectives: (1) To test the use of best–worst scaling
(BWS) experiments in valuing different types of
biomedical and health research impact, and (2) to
explore how different types of research impact are
valued by different stakeholder groups.
Design: Survey-based BWS experiment and discrete
choice modelling.
Setting: The UK.
Participants: Current and recent UK Medical
Research Council grant holders and a representative
sample of the general public recruited from an online
panel.
Results: In relation to the study’s 2 objectives: (1) we
demonstrate the application of BWS methodology in
the quantitative assessment and valuation of research
impact. (2) The general public and researchers
provided similar valuations for research impacts such
as improved life expectancy, job creation and reduced
health costs, but there was less agreement between the
groups on other impacts, including commercial
capacity development, training and dissemination.
Conclusions: This is the second time that a discrete
choice experiment has been used to assess how the
general public and researchers value different types of
research impact, and the first time that BWS has been
used to elicit these choices. While the 2 groups value
different research impacts in different ways, we note
that where they agree, this is generally about matters
that are seemingly more important and associated with
wider social benefit, rather than impacts occurring
within the research system. These findings are a first
step in exploring how the beneficiaries and producers
of research value different kinds of impact, an
important consideration given the growing emphasis
on funding and assessing research on the basis of
(potential) impact. Future research should refine and
replicate both the current study and that of Miller et al
in other countries and disciplines.
INTRODUCTION
The assessment of the non-academic impact
of research is not new,1 but there is
a growing interest internationally in
methodological approaches to identify and
measure these research impacts.2–6 In the
UK, research impact assessment was institu-
tionalised through the 2014 Research
Excellence Framework (REF), which
included the review and grading of 6975
four-page impact case studies by researchers
and research users.7 The results of REF are
used to allocate around £1.6 billion annually
of research funding to English Higher
Education Institutes, 20% (or £320 million/
year) of which is determined by impact
beyond the research system, emphasising the
need for robust, fair and transparent assess-
ments of research impact.
Strengths and limitations of this study
▪ This study contributes to the evidence base on
how different stakeholder groups (researchers
and the general public) value different types of
research impact, an area in which there is a lack
of methodological and empirical research.
▪ This study is important because research
funders are increasingly interested in measuring
(and rewarding) the societal (or non-academic)
impact of research.
▪ We demonstrate the first application of survey-
based best worst scaling methodology in the
quantitative assessment of research impact and
show that the general public and researchers
value research impacts in different ways.
▪ There are limitations related to the samples used,
in that the general public sample was not fully
representative of the population and the drop-out
rate for the researcher sample was high.
▪ The conclusions should not be over-interpreted
given the methodological nature of the research,
including the complex mechanisms for eliciting
valuations, and the fact that our methodology
does not reveal reasons for the differences we
observe. Further research in this area is
recommended.
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There is strong evidence that research makes a signiﬁ-
cant contribution to society,8–11 and that contribution
manifests itself in different ways.12 13 For example, we
know that the total economic return from biomedical
and health research is between 24% and 28%,9 11 and
from analysis of the REF impact case studies that there
are a wide variety of impact topics.13 These beneﬁts
might occur within the research system itself or more
widely in areas such as healthcare, the environment,
technology, the economy or culture. However, there
remains a lack of methodological and empirical research
on how the public value research impact14 15 and how
valuations may vary between stakeholder groups.16
To address this issue, we undertook online surveys
with a representative sample of the UK public as well as
current and recent Medical Research Council (MRC)
grant holders to elicit their relative valuation of different
types of research impact. Using a method known as
‘best–worst scaling’ (BWS),17 we asked survey partici-
pants to compare statements about different types of
impact. An example of an impact statement would be:
‘research helps create new jobs across the UK’ or
‘research contributes to care being provided more
cheaply without any change in quality’.
BWS is a preference elicitation method that helps
understand how respondents choose or rank ‘best’ and
‘worst’ items in a list.17 In recent years, the method has
gained popularity in health and social care as well as
other disciplines.18–20 For example, in the development
of the Adult Social Care Outcome Toolkit (ASCOT)
measure, BWS was employed to establish preference
weights for social care-related quality of life domains.18
Likewise, Coast et al20 used BWS to develop an index of
capability for older people, focused on quality of life,
with an intended use in decision-making across health
and social care in the UK.
The results of the BWS survey were used to develop a
model that elicited the perceived value of different types
of research impact for different groups and segments of
survey respondents, including whether the public have
different valuations from researchers. This matters as
the scientiﬁc community and research users are increas-
ingly asked to assess potential and actual research
impact as part of assessment processes, but have no
empirical basis on which to value different types of
impact.
To the best of our knowledge, this is the second time
this type of analysis has been undertaken. The ﬁrst
study, funded by Canada’s national health research
agency, was a cross-sectional, national survey of basic bio-
medical researchers and a representative sample of
Canadian citizens. The survey assessed preferences for
research outcomes across ﬁve attributes using a discrete
choice experiment.16 The authors concluded that citi-
zens and researchers fundamentally prioritised the same
outcomes for basic biomedical research. Notably, they
prioritised traditional scientiﬁc outcomes and devalued
the pursuit of economic returns.
The speciﬁc objectives of the current study are to:
1. Contribute methodologically to the assessment of
research impact, by adapting BWS to the analysis of
the relative valuations of research impact; and
2. Develop our understanding of how different types of
research impact are valued by different stakeholder
groups.
Below we provide details of the study population and
method. In the Results section, we describe the
characteristics of those who responded to the survey and
present the best ﬁt BWS models for health and biomed-
ical researchers and the general public. In the conclu-
sion we explore the strengths and limitations of our
approach, and draw out key observations from our
analysis.
METHODS
In this section, we describe: the BWS method; the study
population; the two main stages of developing the survey
instrument (deﬁning and categorising the impacts of
health and biomedical research, and constructing and
testing the survey); the survey implementation and the
data analysis carried out. Figure 1 provides an overview
of the stages of the study.
BWS method
We applied ‘attribute-level’ BWS,21 where we developed
a set of lists that included different types (or ‘attributes’)
of research impact each with varying degrees (or
‘levels’) of intensity. The respondents chose the ‘most
important’ (best) and ‘least important’ (worst) impact
from a series of lists. To elicit more information on the
preference data, and to be able to more robustly deter-
mine the relative importance of the different types and
degrees of research impact, we also asked respondents
to choose the ‘second most important’ (second best)
and ‘second least important’ (second worst) impacts
from each list. Further details on the BWS method are
provided in online supplementary ﬁle 1, while informa-
tion on the modelling of respondents’ data is provided
under ‘data analysis’ below.
Study population
The study focused on two populations—the general
public and biomedical and health researchers—and dif-
ferent ‘segments’ or subpopulations within those popu-
lations. The general public participants were recruited
from ResearchNow’s internet panel. ResearchNow is a
market research company that provides access to online
panels of the public for surveys.22 We contracted
ResearchNow for 1000 completed surveys based on rep-
resentative quotas set on age, gender and regions in the
UK. While no monetary incentive was offered to the
researchers, the participants from the general public are
paid by the market research agency for each survey they
complete. For the general public, the questionnaire
included a set of questions extracted from the Public
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Attitudes to Science 2014 study.23 These questions
allowed individuals to be assigned to a segment based
on their attitudes towards science.
The population of biomedical and health researchers
was deﬁned as all principal investigators who had held
MRC funding between April 2006 and November 2014
(n=4708), regardless of whether the grant was still active,
but excluding anyone who was not expected to enter
grant information in Researchﬁsh (a research evaluation
data capture platform). The survey email invitations
were sent to all 4708 researchers (except those used in
the pilot). For researchers, the population segments
were based on one of eight research activity code groups
(eg, ‘underpinning research’, ‘health services research’,
etc) from the Health Research Classiﬁcation System
(HRCS).24
Defining and categorising the impacts of biomedical and
health research
In this section, we describe the development of the
content of the survey— that is, various kinds of impacts
and ways of categorising them. This involved a literature
review, focus groups and researcher interviews. The
development phase is summarised here, with additional
details provided in online supplementary ﬁle 2.
Literature review
We reviewed the literature with the aim of: (1) identify-
ing a range of potential impacts of research; (2) investi-
gating different ways of classifying impacts; and (3)
producing a long list of possible categories and types of
impact that could be tested in focus groups and inter-
views. The review largely covered grey literature as well
as some academic literature and focused on a limited set
of key sources known to the project team. It is sum-
marised in online supplementary ﬁle 2. The main
output of the review was a draft categorisation of
research impacts for testing in the interviews and focus
groups, as shown in table 1.
Focus groups and researcher interviews
Focus groups with members of the public and interviews
with individual researchers were used to reﬁne the types
of research impacts to be valued in the survey. Both
methods aimed to identify the impacts the public and
researchers expect to come from research, whether
there is a shared understanding, how they could be cate-
gorised and how they might be measured.
Four focus groups over two waves were held with the
general public. After an opening discussion about how
to deﬁne biomedical and health research, the majority
Figure 1 Overview of methods.
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of the time in the groups was used to discuss types of
impact, initially by asking participants to suggest ideas,
then prompting discussion on any from our draft impact
framework that had not been mentioned. For each item
discussed, we aimed to determine if people considered
it to be a possible impact of research, how it might be
categorised (eg, health, economic, scientiﬁc) and how it
might be measured. Details of the focus groups, includ-
ing the topic guide, are provided in online supplemen-
tary ﬁle 2, and the key observations are summarised in
box 1.
In addition to the focus groups, we undertook a small
number of interviews (n=9) with biomedical and health
researchers. Details of how the interviewees were
selected, the interview protocol and the key observations
are in online supplementary ﬁle 2. Interviewees were
asked about their understanding of research impact, the
kinds of impact that research in their ﬁeld might have,
and how these impacts might be categorised. We asked
speciﬁcally about any items from our draft framework
that were not mentioned unprompted by the
interviewee.
When asked what they understood by the term
‘impact’ and to provide examples from their ﬁeld, inter-
viewees demonstrated a detailed and consistent aware-
ness of research impact, particularly with respect to
impact occurring outside the research system. Many
referred to REF, and in conducting the interviews in the
wake of this exercise, it is difﬁcult to establish the extent
to which this may have inﬂuenced perceptions of
impact. Interviewees also referred to the research coun-
cils’ increased emphasis on downstream impact, men-
tioning the need to outline potential beneﬁts in funding
applications. This is, perhaps, unsurprising given that
interviewees were all MRC grant holders and were also
aware that the present study was supported by the MRC.
Researchers interviewed were broadly in agreement with
the draft framework developed from the literature, both
Box 1 Key observations from the focus groups
Definition of research
Following brainstorming on the evocation of the word ‘research’,
participants agreed with our proposed definition that research is
‘studying something so that we (as humankind) can understand
better how it works’. Health research and medical research were
seen as slightly different, with health research considered as a
broader term relating to research into health and lifestyle, under-
standing causes, and understanding ‘who suffers from what’. In
contrast, medical research was considered as being more tech-
nical, focused on looking for cures and usually thought of as con-
cerning drug development. We used the term ‘biomedical and
health research’ in the final survey to encourage participants to
think about a range of research.
Research impact
Research impacts from health and medical research suggested by
participants were focused on better health, better quality of life
and longevity. Hence, the purpose of medical research was gener-
ally seen as producing cures and ways of preventing illness and,
to a lesser extent, improving palliative care. Most of the other
impacts in our draft framework were also considered feasible
once suggested by the facilitator.
Research process
Generally, little was known about research processes, infrastruc-
ture and practices, such as academic journal publications. This
led to the exclusion of statements referring to technical or specia-
lised aspects of the research process in the final survey (eg, dif-
ferent types of journal).
Table 1 Draft categorisation of impacts, developed from the existing literature
Category
Knowledge
production
and research
targeting
Capacity
building
Innovative and
economic impact
Health and
health sector
benefit
Policy and
public services
(other than
health)
Public
engagement,
dissemination,
culture and
creativity
Types of
impacts and
measures of
those
impacts
included in
this category
Volume and
quality
measures
Future
funding
Esteem
measures
Number and
quality of
researchers
trained
Collaboration
and
networking
Wider
participation in
research
New products and
process
developed
New businesses
(spinouts)
Benefits to
companies
Job creation,
workforce
development and
increased
economic
competitiveness
Impact on
guidelines/
policy/
professional
training or
development in
health
Impact on
practice
including
saving NHS
money
Impact on
health and
well-being
Changes to
policy outside of
health
Improvements in
the delivery of
public services
(outside of
health)
Benefits to
public well-being
and society
more widely
Number and
range of
dissemination and
outreach activities
Increased public
understanding of
and engagement
with science
NHS, National Health Service.
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in terms of the overall domains representing a logical
classiﬁcation of impacts, and the speciﬁc items within
them being impacts that could reasonably be expected
to come from research. Five items in the draft frame-
work were not considered by interviewees to be impacts
and so were removed. These are detailed in online sup-
plementary ﬁle 2.
Constructing and testing the survey instrument
Findings from the literature review, focus groups and
researcher interviews were used to inform the develop-
ment of a list of attributes and levels for the BWS experi-
ment, the key considerations being that the impacts
used were both well understood and considered as feas-
ible outcomes of biomedical and health research by
both populations. The survey instrument was then tested
through cognitive interviews and a pilot. Additional
details of the survey construction and testing are pro-
vided in online supplementary ﬁle 3.
For the general public, the survey questionnaire
included screening questions, an introduction to the
BWS experiment and its tasks, questions relating to atti-
tudes to science, and sociodemographic questions.
Screening questions asked respondents about their age,
gender, region of residence, social grade and work
status. For researchers, the survey questionnaire
included questions on research background, job title,
clinical experience (if any), an introduction to the BWS
experiment and its tasks, and sociodemographic ques-
tions. Respondents completed the survey by answering
the questions in the same order. The survey could be
saved and completed in multiple sessions. The
researcher questionnaire was shorter than that for the
general public.
The BWS section of both surveys was based on the
same experimental design as described in online supple-
mentary ﬁle 1. It consisted of eight tasks per respondent.
In each task, the respondent was asked to select the
most important, least important, second most important
and second least important impacts from the list of eight
impacts. The order of impacts in this list was randomised
between tasks but was kept the same within a task.
Cognitive interviews
The questionnaire was tested in cognitive interviews with
six members of the public and two researchers as
detailed in online supplementary ﬁle 3. Cognitive inter-
views are a structured, systematic interview technique
used to understand the cognitive processes respondents
use when interpreting and responding to questions. The
aim of the cognitive interviews was to test the near ﬁnal
survey instrument in terms of its wording and layout,
and identify any aspects that might be considered
ambiguous or cause confusion.25 The cognitive inter-
views proved valuable in reﬁning the structure and
wording of the survey instrument, in particular conﬁrm-
ing that statements should be short, use varied wording
to highlight differences between levels and be ordered
randomly in each task, and that the maximum number
of statements that it was manageable to consider in one
task was eight. Further details are provided in online
supplementary ﬁle 3.
Pilot
The revised survey instruments were then tested in a
pilot with samples of MRC grant holders and the
general public. This resulted in simpliﬁcation of the
BWS experiment to reduce respondent burden. Further
details of the pilot are provided in online supplementary
ﬁle 3.
Based on the results of the pilot and cognitive inter-
views, the attribute list was ﬁnalised in an internal work-
shop with all the researchers involved in the study. Final
attributes and levels are presented in table 2 and an
example task is presented in the screen shot in ﬁgure 2.
Both questionnaires are provided in online supplemen-
tary ﬁle 4.
Survey implementation
The main stage of data collection was undertaken in
February and March 2015. All 4620 researchers who did
not participate or respond to the pilot were invited to
take part in the main survey. In order to encourage
researchers to participate, the study was publicised
through the MRC’s blog and Twitter, and individual
researchers were sent up to three follow-up emails, each
of which contained the link to the survey. A fresh
sample of the general public was provided by
ResearchNow, who hosted the survey, contacted respon-
dents and collected the data.
Data analysis
The data analysis in this study comprised two stages: (1)
descriptive analysis and (2) modelling of the BWS data.
The aim of the descriptive analysis was to summarise
the proﬁles of the participants in the general population
and biomedical and health researcher samples by socio-
demographic and other characteristics. We also con-
ducted quality checks on the BWS data using three
exclusion criteria as detailed in online supplementary
ﬁle 5. The remaining data in both samples were then
tested for representativeness against various sociodemo-
graphic characteristics (see online supplementary ﬁle 5
for further details). Finally, we constructed segments
within the researcher and general population samples
deﬁned by research activity codes and their attitudes to
science, respectively (see online supplementary ﬁle 5).
In the second stage of the analysis, modelling of the
BWS data was conducted at the respondent level using
discrete choice analysis.26 The aim of the modelling was
to derive weights reﬂecting the relative importance of
the research impact levels for different stakeholder
groups. The probability of an individual respondent
choosing a research impact level as the ‘most important’
(best) among a set of research impacts (attribute levels)
can be modelled within a multinomial logit framework
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as described in online supplementary ﬁle 1. The esti-
mated coefﬁcients (weights) of each research impact
can then be expressed on a common scale allowing one
to infer how respondents or different groups of respon-
dents value different types of research impact. In this
stage, we also examined how individuals’ preferences
varied according to their attitudes to science (in the
general population sample) and research activity codes
(in the researcher sample).
RESULTS
Data summary
Of the 4620 researchers invited, 1431 participated in the
main survey questionnaire (response rate 31%). Out of
the 1431 researchers, 465 provided partial responses to
survey questions, including 260 researchers who did not
complete any of the BWS tasks. As a result, the completion
rate, deﬁned as the proportion of researchers who pro-
vided no missing data (966) over the total number of
Table 2 Attributes and levels (domains and impacts) used in the surveys
Level
Domain 1 2 3 4
Knowledge
(KNOW)
Research replicates the
findings of others,
helping to strengthen the
evidence of how some
things work (KNOW1).
Research results in a
new finding, helping to
focus subsequent
research activities
(KNOW2).
Research shows that
something does not work,
eliminating the need for
further investigation
(KNOW3).
Research reviews and
combines previous
findings, identifying
areas of consistency
and difference
(KNOW4).
REF impact
(IMPACT)
Research generates
knowledge that is world
leading (IMPACT1).
Research generates
knowledge that is
internationally excellent
but which falls short of
the highest standards of
excellence (IMPACT2).
Research generates
knowledge that is
recognised internationally
(IMPACT3).
Research generates
knowledge that is
recognised nationally
(IMPACT4).
Training
(TRAIN)
Research trains young
people who go on to
work in industry as
scientists (TRAIN1).
Research trains young
people, who become
researchers and lecturers
in universities (TRAIN2).
Research trains doctors
and nurses who also
become researchers
(TRAIN3).
Research trains young
researchers who go on
to work outside of
science (eg, in
business, in the civil
service, as teachers)
(TRAIN4).
Jobs ( JOBS) Research helps create
new jobs in the
university ( JOBS1).
Research helps create
new jobs in one town
( JOBS2).
Research helps create
new jobs in one region
( JOBS3).
Research helps create
new jobs across the UK
( JOBS4).
Private funding
(PVT)
Research contributes to
a follow-up study in the
UK being funded by a
company (PVT1).
Research contributes to
an existing UK research
facility being partly
funded by a company
(PVT2).
Research contributes to a
new UK research facility
being set up by a
company (PVT3).
Research contributes to
a company deciding to
move a major part of its
operations to the UK
(PVT4).
Life expectancy
(QOLY)
Research contributes to
the development of a
treatment that would
increase life expectancy
by 3 months for the 10%
of adults living with a
common disease in the
UK (QOLYR, QOLYRC).
Research contributes to
the development of a
treatment that would
increase life expectancy
by 6 months for the 10%
of adults living with a
common disease in the
UK (QOLYR, QOLYRC).
Research contributes to
the development of a
treatment that would
increase life expectancy
by 1 year for the 10% of
adults living with a
common disease in the
UK (QOLYR, QOLYRC).
Research contributes to
the development of a
treatment that would
increase life expectancy
by 3 years for the 10%
of adults living with a
common disease in the
UK (QOLYR, QOLYRC).
Cost of care
(COST)
Research contributes to
care being provided
more cheaply without
any change in quality
(COST1).
Research contributes to
better care being
provided at the same
cost (COST2).
Research contributes to
better care being
provided at a higher cost
(COST3).
Research contributes to
more choice of care at
the same quality and
cost (COST4).
Dissemination
(DISS)
Researchers talk in
schools about their
research (DISS1).
Researchers give
interviews to the media
about their research
(DISS2).
Researchers give public
lectures about their
research (DISS3).
Researchers consult the
public to help set
research priorities
(DISS4).
REF, Research Excellence Framework.
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participating researchers (1431), was 68% (table 3). The
total number of researchers with fully or partially com-
pleted BWS tasks was 1171. Just over half (52.5%) of the
respondents who completed the survey took more than
15 min to do so, while 12.5% completed it in 10 min or
less.
We also received 1000 fully completed questionnaires
from members of the general public who were members
of the internet panel administered by ResearchNow. As
is the norm with internet panels, we prespeciﬁed quotas
to generate a sample representative of key characteristics
including age, gender, social grade and geographic
region. Given the nature of the sample, it is not possible
to estimate a survey response rate. However, while none
of the general public responses had missing data,
ResearchNow estimated the completion rate to be 90%.
The majority (67%) of the respondents who completed
the survey took more than 15 min, while 7.6% com-
pleted it in 10 min or less.
Table 3 presents a summary of the quality checks on
the BWS data (note: numbers are not exclusive to each
category).
We checked the representativeness of the responses
used in the modelling against various sociodemographic
characteristics (see online supplementary ﬁle 5 for
further detail). The general public respondents from
the online panel were selected to be representative
against the quotas set for gender, age and region, based
on mid-2013 Ofﬁce for National Statistics (ONS) popula-
tion estimates. ResearchNow found it difﬁcult to meet
the quota for the Yorkshire and Humber region; hence,
additional respondents were recruited from other north-
ern regions instead. The distribution of 728 general
public respondents who provided preferences for BWS
choice models matched well with the targets for gender
and region. Our sample under-represents the youngest
age group and over-represents the oldest. It also contains
a higher proportion of higher social grades than the
general population.
The MRC provided age, gender and ethnicity of
researchers in the grant database, and this was com-
pared with the proportions observed in the survey
responses used for modelling. Our sample contains a
greater proportion of women than the overall popula-
tion of MRC-funded researchers. It also over-represents
white, mixed and black researchers, and under-
represents Asian/Asian British researchers.
Modelling
The preferences provided by the researcher and general
public surveys were modelled separately, using the
method established in prior BWS studies in other
ﬁelds.27–29 The model results are presented in table 4.
Each model coefﬁcient in this table represents a
Figure 2 Example of best–worst scaling tasks.
Table 3 Response summary for both surveys
Researchers General population
Response rate 31% NA
Number of total responses 1431 1113
Number of complete responses (no missing data) 966 1000
Number of respondents with missing data 465 113*
Number of respondents who completed at least one
BWS scaling task
1171 1000
Survey completion rate 68% 90%
Observation exclusion criteria
Completed 8 BWS tasks under 5 min 2 (0.2% of complete responses) 170 (2.2%)
Did not understand most of BWS tasks 37 (4% of complete responses) 102 (10%)
Unable to make comparisons in most BWS 146 (15% of complete responses) 129 (13%)
BWS, best–worst scaling; NA, not available.
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Table 4 General public model and researchers estimates
Model group General public Researchers
Description of
research impact
Coefficient
name Coefficient† (95% CI) Coefficient† (95% CI)
Research contributes to care being provided more
cheaply without any change in quality.
COST1 4.582 (4.318 to 4.847) 4.087 (3.851 to 4.324)
Research contributes to better care being provided at the
same cost.
COST2 4.613 (4.349 to 4.876) 4.632 (4.397 to 4.868)
Research contributes to better care being provided at a
higher cost.
COST3 2.278 (2.029 to 2.527) 2.557 (2.322 to 2.793)
Research contributes to more choice of care at the same
quality and cost.
COST4 4.349 (4.087 to 4.611) 3.168 (2.922 to 3.415)
Researchers talk in schools about their research. DISS1 0.884 (0.668 to 1.1) 1.085 (0.866 to 1.304)
Researchers give interviews to the media about their
research.
DISS2 0 NA 0 NA
Researchers give public lectures about their research. DISS3 0.308 (0.097 to 0.519) 0.937 (0.719 to 1.155)
Researchers consult the public to help set research
priorities.
DISS4 1.917 (1.677 to 2.157) 1.813 (1.576 to 2.05)
Research generates knowledge that is world leading. IMPACT1 3.572 (3.305 to 3.839) 3.487 (3.248 to 3.726)
Research generates knowledge that is internationally
excellent but which falls short of the highest standards of
excellence.
IMPACT2 4.385 (4.12 to 4.649) 5.04 (4.804 to 5.277)
Research generates knowledge that is recognised
internationally.
IMPACT3 3.817 (3.549 to 4.085) 3.868 (3.631 to 4.106)
Research generates knowledge that is recognised
nationally.
IMPACT4 3.729 (3.466 to 3.992) 3.662 (3.424 to 3.899)
Research helps create a small number of new jobs in the
university.
JOBS1 1.646 (1.419 to 1.874) 1.265 (1.048 to 1.482)
Research helps create a small number of new jobs in
one town.
JOBS2 1.489 (1.263 to 1.715) 0.154* (−0.049 to 0.356)
Research helps create a substantial number of new jobs
in one region.
JOBS3 1.832 (1.594 to 2.069) 1.153 (0.939 to 1.367)
Research helps create a substantial number of new jobs
across the UK.
JOBS4 3.345 (3.081 to 3.61) 3.269 (3.036 to 3.503)
Research replicates the work of others, helping to
strengthen the evidence of how some things work.
KNOW1 4.554 (4.287 to 4.822) 5.512 (5.274 to 5.75)
Research results in a new finding, helping to focus
subsequent research activities.
KNOW2 2.618 (2.365 to 2.871) 3.418 ( 3.176 to 3.66)
Research shows that something does not work,
eliminating the need for further investigation.
KNOW3 4.036 (3.766 to 4.305) 5.086 (4.847 to 5.325)
Research reviews and combines previous findings,
identifying areas of consistency and difference.
KNOW4 3.521 (3.256 to 3.787) 2.876 (2.626 to 3.127)
Research contributes to a follow-up study in the UK
being funded by a company.
PVT1 2.805 (2.553 to 3.056) 1.052 (0.839 to 1.265)
Research contributes to an existing UK research facility
being partly funded by a company.
PVT2 2.794 (2.544 to 3.045) 1.07 (0.854 to 1.286)
Research contributes to a new UK research facility being
set up by a company.
PVT3 2.796 (2.542 to 3.05) 1.699 (1.476 to 1.922)
Research contributes to a company deciding to move a
major part of its operations to the UK.
PVT4 2.968 (2.707 to 3.229) 2.097 (1.859 to 2.335)
Research trains young researchers who become
researchers in industry.
TRAIN1 3.713 (3.453 to 3.974) 3.081 (2.848 to 3.314)
Research trains young researchers who become
university professors.
TRAIN2 3.368 (3.109 to 3.626) 3.768 (3.535 to 4.002)
Research trains young researchers who become doctors
and nurses.
TRAIN3 3.775 (3.511 to 4.038) 2.832 (2.595 to 3.069)
Research trains young researchers who go on to work
outside of science (eg, in business, in the civil service,
as teachers).
TRAIN4 2.449 (2.193 to 2.704) 2.094 (1.857 to 2.332)
Continued
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preference weight measured as latent utility (which
does not have a speciﬁc unit). To allow comparison
between the preferences of researchers and the
general public, we converted the coefﬁcients of both
groups to a common scale using a tangible unit—‘add-
itional years of life expectancy’ (AYLE), based on each
group’s preferences for the life expectancy domain in
the BWS task.
For example, the general public’s preference for
‘research contributes to a company deciding to move a
major part of its operations to the UK’ is equivalent to
their preference for 7.21 AYLE for 10% of adults living
with a common chronic disease in the UK (compared
with 3.94 additional years for the researcher group).
This conversion both facilitates the understanding of
preferences in a tangible unit and allows comparison of
preferences across groups and between populations.
Further detail on the conversions is provided in online
supplementary ﬁle 5.
The preferences converted into equivalent values of
life expectancy for the general public and researchers
are presented in ﬁgure 3. The transparent bars indicate
where there are not statistically signiﬁcant differences
between the two populations. Across the 28 different
impacts there are statistically meaningful differences in
20 cases, suggesting that the general public and
researchers value research impact in different ways. For
example, the ﬁrst horizontal bar in ﬁgure 3 relates to
the impact statement ‘research replicates the work of
others, helping to strengthen the evidence of how some
things work’. This statement is valued at providing the
equivalent of 11.16 (95% CI 9.77 to 12.55) AYLE by the
general public and 10.36 (95% CI 10.12 to 10.60) AYLE
by researchers. The transparent bars in the ﬁgure indi-
cate that there is no statistically signiﬁcant difference
between the two groups with respect to this statement.
By contrast, the fourth impact statement in ﬁgure 3
—‘research contributes to better care being provided at
the same cost’—is valued more by the general public,
the solid bars indicating that this difference is statistically
signiﬁcant.
Comparative analysis of preferences
Based on the analysis presented in table 4 and ﬁgure 3,
we can infer a number of conclusions on how different
types of research impacts are valued by the general
public and researchers, summarised in box 2. The areas
of agreement between the two groups are generally
those relating to wider societal impact. For example,
improved life expectancy, cost of healthcare and job cre-
ation (points 1–3) are all considered important by
researchers and the public. However, the two groups
differ in their relative valuation of training priorities,
commercial capacity development and dissemination
(points 6–8). We also ﬁnd that both researchers and the
general public rank research presented as ‘internation-
ally excellent’ above that presented as ‘world leading’
(point 5). This is notable because the REF uses these
terms in the opposite order when assessing academic
quality.
For the two group-level models, we also tested differ-
ences in preferences between segments of both popula-
tions. For researchers, the segments were based on
research activity codes.24 For the general public, each
respondent was assigned to a segment based on their
attitudes towards science, as deﬁned by the set of ques-
tions extracted from the Public Attitudes to Science
2014 study.23 Details of how we implemented this seg-
mentation and the results are provided in online supple-
mentary ﬁle 5. Overall there were only minor
differences between the general public segments, and
when they occurred they were difﬁcult to coherently
interpret. For the researchers, the differences by HRCS
code were more pronounced and had a degree of face
validity. For example, ‘health services researchers’ were
more concerned about healthcare costs than those
involved in ‘underpinning research’.
Table 4 Continued
Model group General public Researchers
Description of
research impact
Coefficient
name Coefficient† (95% CI) Coefficient† (95% CI)
Value of change in 1 year on life expectancy of 10% of
adults living with a common chronic disease in the UK
QOLYR 0.408 (0.363 to 0.453) 0.532 (0.493 to 0.57)
Intercept on life expectancy QOLYRC 4.399 (4.139 to 4.658) 3.959 (3.727 to 4.191)
Impact statement position—bottom most Bottom 0.128 (0.032 to 0.224) 0.395 (0.296 to 0.494)
Impact statement position—second from the top Top2 0.145 (0.078 to 0.213) NA
Impact statement position—top most Top 0.192 (0.125 to 0.258) 0.171 (0.113 to 0.228)
Scale for second worst preference Scale4 0.468 (0.437 to 0.499) 0.365 (0.342 to 0.388)
Scale for second best preference Scale3 0.62 (0.583 to 0.656) 0.577 (0.551 to 0.602)
Scale for worst preference Scale2 0.593 (0.557 to 0.629) 0.489 (0.462 to 0.517)
Scale for best preference(fixed to one) Scale1 1 NA 1 NA
*p=0.132.
†p<0.05 for all estimated model coefficients except where explicitly specified.
NA, not available.
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DISCUSSION
We can identify three key ﬁndings from this study. First,
that it is possible for different types of impacts to be dir-
ectly compared and rated, and that BWS offers a poten-
tially effective way to make such comparisons. Second,
that there are similarities in views between the research-
ers and the public about the relative importance of
social impacts, but also notable differences of opinion
between these groups regarding other research-related
impacts. These differences are important, as researchers
are increasingly asked to make judgements about the
value, or potential value, of research in the award of
public funding. Finally, we note that our ﬁndings differ
from those of a previous study by Miller et al,16 suggest-
ing that further research is required. We explore each of
these in turn.
The study shows the potential of BWS as a method-
ology for the quantitative assessment of research impact.
While a stated preference approach has been used in a
recent Canadian study,16 to the best of our knowledge,
this is the ﬁrst application of the BWS approach for rela-
tive valuation of research impacts. The BWS method-
ology allows quantiﬁcation of preferences and we have
also demonstrated how these preferences can be com-
pared across two discrete groups on a common scale.
Compared with stated preference discrete choice experi-
ments, the BWS methodology uses a simpler choice task
involving less cognitive burden for respondents and can
accommodate a larger number of attributes within each
choice task. Another strength of the study is that it uses
large, national samples of MRC-funded researchers and
the general public. To the best of our knowledge, this is
Figure 3 Preferences for different types of research impact, expressed as additional years of life expectancy (AYLE) for 10% of
adults living with a common chronic disease in the UK. Note that the shaded (non-transparent) boxes illustrate impacts that are
statistically different between the general public and researchers.
Box 2 Key observations arising from best–worst scaling
analysis of the relative valuation of research impact
1. Achieving higher life expectancy for adults living with a
common chronic disease in the UK is one of the highest priorities
for both the general public and researchers—well ahead of com-
mercial and employment benefits.
2. Both researchers and the general public are concerned about
the cost of healthcare provision, but the general public appears to
be more cost-sensitive than the researchers.
3. Both researchers and the general public agree that creating a
substantial number of jobs across the UK through research is
important.
4. Public lectures, school talks and media interviews are among
the least valued impacts by both the general public and biomed-
ical and health researchers.
5. Research presented as internationally excellent is ranked higher
than research presented as world leading by the general public
and researchers, despite the Research Excellence Framework
(REF) using these phrases in the opposite order.
6. The general public prefers the training of future medical profes-
sionals over the training of future academics, while researchers
have the opposite preference. Overall, the general public gives
much higher preference to the ‘training’ domain of impacts com-
pared with the researchers.
7. The general public makes no distinction between different
types of commercial capacity development. Researchers are more
nuanced showing a preference for attracting foreign investment.
The general public also attaches a much higher preference to this
domain compared with the researchers.
8. In the ‘dissemination’ domain the general population values all
research impacts higher than researchers, except the impact
‘researchers give public lectures about their research’ which is
valued more by the researchers than the general public.
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the ﬁrst study to contrast valuation of research impact
between UK biomedical researchers and citizens. Within
a given sample, BWS enables comparison of valuations
of research impact by simply comparing the marginal
utility estimates; this is an improvement over discrete
choice experiments, which unless carefully designed, do
not allow for comparisons of attribute levels (research
impacts) across different attributes (domains).30
The second principle ﬁnding is that the general
public and researchers value research impacts in differ-
ent ways. However, it is also the case that when the two
groups are in agreement, this is generally about matters
that are seemingly more important and associated with
wider social beneﬁt (eg, life expectancy, cost of health-
care, job creation), rather than impacts associated with
the research system, where the two groups tend to dis-
agree (eg, training, commercial capacity development).
Either way, this is important as the UK research councils
‘encourage researchers to consider the potential contri-
bution that their research can make to the economy and
society from the outset, and the resources required to
carry out appropriate and project-speciﬁc knowledge
exchange impact activities’.31 As part of their funding
applications, researchers must submit a ‘pathway to
impact’ statement which is peer reviewed by referees
and panel members. Similarly, the funding councils
assessed research impact using a case study approach as
part of the 2014 REF. These case studies were reviewed
by academic peers and non-academic experts providing
a private, public and third sector perspective. However,
in assessing the value of the impact claimed, reviewers
cannot currently draw on comprehensive evidence of
the views of beneﬁciaries (ie, the general public) or the
producers of research (ie, biomedical and health
researchers) to qualify or justify their grading. Indeed
an evaluation of how panels assessed research impact as
part of REF 2014 highlighted this as a concern raised by
panel members.32 In other words, the subjective valu-
ation of research impacts rests on weak empiric founda-
tions. This in turn raises questions about the reliability
of impact assessment and whether current processes are
robust, fair and transparent. The research presented in
this paper is a small ﬁrst step in understanding how
research impacts can be valued. With further research, it
may be possible to use such valuations to develop
metrics for assessing research impact, although we stress
that this is a longer term objective, to be considered
alongside the need for better ways of identifying and
measuring societal impact more generally, and should
not be advocated based on the current study.
Our ﬁnal key ﬁnding is that the results observed differ
from a previous study in this area. To the best of our
knowledge, this is only the second time that a discrete
choice experiment has been used to assess how the
general public and researchers value different types of
research impact, and the ﬁrst time that BWS has been
used to elicit these choices. The results of the current
study are different to those of Miller et al16 who argued
that the similarities between the general public and
researchers were more important than the differences.
We do not believe that the difference between the two
studies can be explained on methodological grounds
(ie, the stated preference method vis-à-vis BWS). That
said, there were two important differences between the
studies. First, the choice context is different. Miller et al
asked respondents to review and assess the impacts using
a scenario of an academic biomedical research team.
Behaviourally, this may induce respondents to respond
as if wearing the hat of an ‘expert reviewer’ rather than
as lay public. The same applies for researchers. Here, we
presented research impact in much broader terms and
not within a given scenario. Second, the selection of
attributes in Miller et al remains within the strict con-
ﬁnes of academic-oriented contributions, namely publi-
cations, trainees, patents and targeted economic
priorities. In this study, we attempted to elicit valuations
from a much broader range of domains and research
impacts within each domain, perhaps also reﬂecting the
Research Council UK’s (RCUK) deﬁnition of research
impact where ‘academic impact forms part of the critical
pathway to economic impacts and societal impact’. That
said, it may also be that there are cultural differences
between the Canadian and British respondents or other
reasons for the differing results. In any case, given the
importance of research impact assessment, it seems that
these two studies need further reﬁnement and replica-
tion both in Canada and the UK, but also in other coun-
tries and for other disciplines.
We note four areas that would merit particular focus
in further studies. First is the need to improve engage-
ment of researchers. A large proportion of respondents
in the researcher sample dropped out prior to fully com-
pleting the survey (32%). A review of the qualitative
feedback submitted through the survey questionnaire
suggested that researchers either felt the survey was pol-
itically motivated; that it did not cover all important
aspects of research impact; or they wished that a ‘none’
option was available in the BWS tasks. Second, a limita-
tion of this study is the representativeness of the internet
recruited panel of the general public. While we were
able to match key demographics such as age and region
of residence with mid-2013 ONS population estimates,
the signiﬁcantly higher proportion of individuals in the
higher National Readership Survey (NRS) Social Grades
in the sample provides an indication that the proﬁle of
respondents related to other characteristics (eg, educa-
tion) may be signiﬁcantly different and thus not repre-
sentative of the general population in the UK. Third,
although we were able to detect differences in view-
points between members of the public and researchers,
we were not able through this study to understand the
reasons for these differences between groups.
Encouraging discussions around why preferences differ
in speciﬁc instances might usefully inform future
research objectives, as well as encourage more nuanced
communication between researchers and the public on
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the potential beneﬁts of research. Finally, further work
in this area could start to work towards the longer term
goal of being able to rate and compare different types of
impact to support decision-making.
To summarise, this work sets out a new approach to
elicit opinions about the relative importance of different
types of research impact and highlights evidence for
some important differences in opinion between
researchers and members of the public. This has impli-
cations for policy-making, since researchers and funders
commonly assess the potential and realised impact of
research as part of funding decision-making processes.
The methods set out here might offer one way to under-
stand and begin to address this, with the potential,
through further research, to develop a way to assess and
compare different types of impact based on empirical
evidence of their relative importance to members of the
public. Exploring this question and these methods
further could help better align publicly funded research
with the needs and priorities of the public, strengthen-
ing accountability and public engagement with science,
and perhaps, ultimately, offering better value to society.
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